Repros Therapeutics, Inc. (RPRX) Posts Wider than Expected Q2 Loss of 21c/Share

Repros Therapeutics, Inc. (NASDAQ: RPRX) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Repros Therapeutics, Inc. (RPRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight